OncRef
Skip to newsletter content
|
SCLCFebruary 2026
0:00 / 2:35
Small Cell Lung Cancer — Monthly Compass
Feb 01–28, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
small cell lung cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • NRG Oncology/Alliance LU005 demonstrated no survival improvement from adding atezolizumab to concurrent chemoradiation in limited-stage SCLC, confirming CRT alone as standard and redirecting innovation toward peri-/post-CRT strategies.
  • Key Clinical Development Updates
    • Amgen’s February 3, 2026 update underscored Imdelltra (tarlatamab‑dlle) as the first FDA‑approved DLL3‑targeting BiTE for post‑platinum ES‑SCLC and detailed ongoing EU/China/Japan regulatory reviews alongside multiple Phase 3 programs spanning first‑line induction, maintenance, and post‑chemoradiation settings.
    • ZG006 (Alveltamig) began U.S. clinical treatment with the first patient treated, marking pipeline expansion of DLL3 T‑cell engagers and expanding trial access across community geographies.
  • Important Clinical Trial Publications
    • A Phase 2 analysis of guadecitabine plus carboplatin in extensive-stage SCLC showed significant global PBMC hypomethylation with NF‑κB pathway modulation and immune‑cell shifts, supporting blood‑based methylation profiling as a non‑invasive response biomarker (NCT03913455; PMID:41757123).
  • Key Conference Updates
    • At the 8th Theranostics World Congress 2026, Molecular Partners presented first‑in‑human imaging and dosimetry for the DLL3‑targeting 212Pb Radio‑DARPin MP0712 demonstrating tumor‑selective uptake with limited normal‑tissue signal and dosimetry supportive of therapeutic dosing.
    • At TTLC 2026, SCLC discussions coalesced around DLL3 as a unifying target spanning radiopharmaceuticals and T‑cell engagers, signaling diversification of modality options in relapse settings.
  • Emerging Themes & Macro-Trends
    • Consolidation of DLL3 across modalities is driving operational readiness imperatives, including DLL3 testing/identification workflows, T‑cell engager toxicity management, and radiopharmaceutical handling capabilities.
    • Advocacy‑aligned funding via the LCRF | AstraZeneca SCLC grants is positioned to accelerate translational strategies, enhance trial accrual, and support real‑world adoption across care settings.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • The FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 (ERBB2) tyrosine kinase domain activating mutations. This approval was based on efficacy data from the Beamion LUNG-1 trial, which showed an objective response rate of 76% in patients who had not received prior systemic therapy for advanced disease.¹ (read more)
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Amgen’s February 3, 2026 Q4/FY 2025 results highlighted the FDA’s November 2025 traditional approval of Imdelltra (tarlatamab‑dlle) for adults with ES‑SCLC after platinum therapy, and noted additional regulatory reviews under way in the EU, China, and Japan alongside multiple Phase 3 studies across ES‑ and LS‑SCLC. The update reiterates Imdelltra’s status as the first FDA‑approved DLL3‑targeting BiTE and outlines a broad registrational program in first‑line induction and maintenance as well as post‑chemoradiation settings. ¹ (read more)
  • Jazz Pharmaceuticals’ February 24, 2026 FY/Q4 2025 press release reported the U.S. FDA approval and U.S. launch of Zepzelca (lurbinectedin) plus atezolizumab as first‑line maintenance therapy for ES‑SCLC, achieved in October 2025. The company framed the approval as expanding Zepzelca’s addressable market and cited ongoing commercial execution in the U.S. following this regulatory milestone. ² (read more)
  • Allarity Therapeutics’ February 3, 2026 press release announced that a VA‑funded Phase 2 trial of stenoparib plus temozolomide in relapsed SCLC opened for enrollment, and the company’s forward‑looking statements referenced potential “regulatory advancement, including under FDA Fast Track designation.” Although primarily a clinical start‑up announcement, the company explicitly flagged prospective Fast Track engagement as part of its regulatory planning. ³ (read more)
Conference
Major Conference Updates
Conference Information
  • IASLC Targeted Therapies of Lung Cancer (TTLC) 2026, Huntington Beach, California, February 18–21, 2026; 8th Theranostics World Congress (TWC) 2026, Cape Town, South Africa, late January with sessions January 30–31 and company webcast February 2, 2026.
  • Overall sentiment: SCLC momentum centered on DLL3 as a unifying target across radiotherapeutics and T‑cell engagers; meanwhile, limited‑stage data temper enthusiasm for concurrent chemo‑IO, underscoring need for smarter sequencing and novel modalities. (read more)
  • Theme 1: DLL3 Radiotherapeutics Move Into Early Clinical Testing
    • Significance: Radiopharmaceuticals add a new modality for chemo‑refractory SCLC, with early human imaging/dosimetry supporting tumor‑selective delivery and a path to therapeutic dosing. (read more)
    • Mechanism insights / clinical impact: MP0712 (DLL3‑targeting Radio‑DARPin carrying 212Pb) showed specific tumor uptake with limited normal‑tissue signal and dosimetry supporting 212Pb therapy; MSK reported DLL3‑binding radioactive agents with improved selectivity in neuroendocrine cancers, highlighting potential for precise cytotoxicity. (read more)
    • Patient populations affected: DLL3‑expressing SCLC and related neuroendocrine carcinomas; candidates post‑platinum with high unmet need. (read more)
  • Theme 2: Next‑Wave DLL3 T‑Cell Engagers Enter U.S. Clinics
    • Significance: Beyond tarlatamab, pipeline expansion is tangible as ZG006 (Alveltamig) initiates U.S. treatment—validating DLL3 as a sustained immunotherapy axis and diversifying options in relapse. (read more)
    • Mechanism insights / clinical impact: ZG006 (Alveltamig) “connects disease‑fighting T cells to cancer cells,” reinforcing the class’s cytolytic synapse approach; early U.S. experience signals feasibility and growing trial access. (read more)
    • Patient populations affected: Adults with recurrent SCLC after standard therapy; initial U.S. trial sites highlight access expansion across community geographies. (read more)
  • Theme 3: Concurrent Chemo‑IO Falls Short in Limited‑Stage SCLC
    • Significance: NRG Oncology/Alliance LU005 found no survival improvement from adding atezolizumab to concurrent chemoradiation, clarifying that CRT alone remains standard and redirecting innovation toward peri‑/post‑CRT strategies. (read more)
    • Mechanism insights / clinical impact: Negative concurrent IO signal suggests timing/immune contexture may blunt benefit in LS‑SCLC, arguing for alternative sequences or different modalities (e.g., DLL3‑directed agents) to augment cure intent. (read more)
    • Patient populations affected: Limited‑stage SCLC receiving curative‑intent CRT; practice impact is immediate with maintained SOC. (read more)
  • Theme 4: Funding Catalysts Target SCLC Outcomes and Advocacy
    • Significance: New LCRF | AstraZeneca SCLC awards channel resources to treatment‑improvement strategies and advocacy‑driven outcome gains, sustaining pipeline breadth between congress milestones. (read more)
    • Mechanism insights / clinical impact: Grants emphasize translational strategies and patient‑advocacy frameworks that can speed study design, accrual, and real‑world adoption across care settings. (read more)
    • Patient populations affected: Broad SCLC community, with focus on improving outcomes across stages and care access. (read more)
  • Significance
    • Expected clinical or translational readouts: MP0712 Phase 1/2a initial safety/activity data anticipated in 2026; continued U.S. enrollment for ZG006 (Alveltamig). (read more)
    • Regulatory or policy implications: No near‑term changes from February data; LU005 supports existing LS‑SCLC standards without adding concurrent IO. (read more)
    • Potential shifts in standard of care: Radiotherapeutics and next‑gen DLL3 engagers could reshape post‑platinum management pending efficacy/safety; LS‑SCLC remains CRT‑anchored. (read more)
    • Strategic implications: Prioritize DLL3 testing/identification workflows; build site readiness for T‑cell engager toxicities and radiopharmaceutical handling; leverage advocacy‑backed funding to de‑risk early combinations and peri‑CRT strategies. (read more)
Publications Related to Approved Drugs
Unknown Drug
There are no new publication updates during the 2026-02-01 to 2026-02-28 for small cell lung cancer.
New Publications Related to Drugs in Clinical Trial Development
Phase 2
Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients. This study evaluated the epigenetic and immune impact of guadecitabine combined with carboplatin in patients with extensive-stage small cell lung cancer, revealing significant global hypomethylation and alterations in key signaling pathways like NF-κB within peripheral blood mononuclear cells. The analysis identified distinct shifts in immune cell populations, suggesting that blood-based methylation profiling can serve as a non-invasive biomarker to monitor treatment response and immune modulation in this setting. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in small cell lung cancer updated from 2026-02-01 to 2026-02-28:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation--1---1
Not Yet Recruiting652217-41
Recruiting5843676411216
Available-------
Approved for Marketing-------
Active, Not Recruiting201625120-82
Completed11--5-7
Total85651158731347
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Palbociclib, Binimetinib NCT03170206 COMPLETED Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer 2025-12-31
PF-08046032, Sasanlimab NCT06870487 ACTIVE_NOT_RECRUITING An Open-Label Phase 1 Study to Evaluate PF-08046032 as Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies 2026-02-27
Fluorouracil, AB598, Oxaliplatin, Leucovorin, Zimberelimab NCT05891171 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-03
Etoposide, Carboplatin, Debio 0123 NCT05815160 ACTIVE_NOT_RECRUITING A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy 2026-03
MEDI5752, Gemcitabine, Cisplatin, Nab-paclitaxel, Danvatirsen, AZD2936, Pemetrexed, Carboplatin, Durvalumab, Oleclumab NCT03819465 ACTIVE_NOT_RECRUITING A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN) 2026-03-26
Docetaxel, Ceritinib NCT03611738 ACTIVE_NOT_RECRUITING Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC 2026-04
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Toripalimab NCT05888402 ACTIVE_NOT_RECRUITING The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer 2026-03-20
Osimertinib + Savolitinib, Savolitinib + Placebo NCT04606771 ACTIVE_NOT_RECRUITING A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib 2026-03-30
Tepotinib, Osimertinib NCT03940703 ACTIVE_NOT_RECRUITING A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) 2026-05-01
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Atezolizumab, Tiragolumab NCT06267001 COMPLETED A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy 2025-12-16
Cisplatin, Nab-paclitaxel, : Pembrolizumab/Vibostolimab, : Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel NCT05226598 COMPLETED A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) 2026-01-09
: Pembrolizumab/Vibostolimab, : Pembrolizumab NCT04738487 COMPLETED A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer 2026-01-27
Cisplatin, : Pembrolizumab, Olaparib, Carboplatin, Pemetrexed NCT03976323 COMPLETED A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) 2026-01-29
Placebo, Nab-paclitaxel, : Pembrolizumab, Olaparib, Carboplatin, Paclitaxel NCT03976362 COMPLETED A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 2026-01-30
Docetaxel, DS-1062a NCT04656652 ACTIVE_NOT_RECRUITING Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01) 2026-01-31
Lurbinectedin, Irinotecan, Topotecan NCT05153239 ACTIVE_NOT_RECRUITING A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial) 2026-04
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.